Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BA2401
- Development stage
- Preclinical
- Lead developer
- T-Cypher Bio
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
BA2401 is a bispecific T cell engager (TCE) antibody being developed by T-Cypher Bio for the treatment of solid tumors. The molecule is designed to target the PRAME (Preferentially Expressed Antigen in Melanoma) protein specifically when presented by the HLA-A*24:02 major histocompatibility complex (MHC) allele. By simultaneously binding to the CD3 receptor on T cells, BA2401 recruits and activates cytotoxic T lymphocytes to the tumor site, facilitating the targeted destruction of PRAME-expressing cancer cells. As of early 2024, the program is in the lead optimization stage of preclinical development.
- Other names
- BA2401-T-Cypher Bio-PRAME A24-CD3-T cell engager-bispecific antibody-Solid tumorsBA-2401-T-Cypher Bio-PRAME A24-CD3-T cell engager-bispecific antibody-Solid tumorsBA 2401-T-Cypher Bio-PRAME A24-CD3-T cell engager-bispecific antibody-Solid tumorsPRAME A24-CD3 T cell engager
02
Targets
CD3 (T-cell surface glycoprotein CD3)MAGE (Melanoma-associated antigen family)
Beyond the preview
Go deeper on BA2401.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BA2401.